Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezatapopt (PC14586) and Itraconazole PK Study
NCT06362642Phase 1Completed
- Sponsor
- PMV Pharmaceuticals, Inc.
- Start
- Mar 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rezatapopt in solid tumor, sponsored by PMV Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration (Cmax) of PC14586 at 6 weeks, Area Under the Curve from Time Zero to Infinity (AUC0-inf) of PC14586 at 6 weeks and 2 more. Started Mar 2024; status: completed.
02
Drugs
rezatapopt
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06362642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362642.